RespireRx Pharmaceuticals Inc. (RSPI) financial statements (2022 and earlier)
Company profile
| Business Address |
126 VALLEY ROAD GLEN ROCK, NJ 07452 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Cash and cash equivalents | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Prepaid expense | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Deferred costs | 0 | ||||||||
| Other undisclosed current assets | 0 | 0 | 0 | 0 | |||||
| Total current assets: | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | (0) | 0 | 0 | 0 | |||||
| Prepaid expense | 0 | 0 | 0 | 0 | 0 | ||||
| Other undisclosed noncurrent assets | 0 | ||||||||
| Total noncurrent assets: | 0 | 0 | 0 | 0 | 0 | ||||
| TOTAL ASSETS: | 0 | 0 | 0 | 0 | 0 | 0 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 4 | 3 | 3 | 2 | 1 | 2 | |||
| Employee-related liabilities | 2 | 1 | 0 | 2 | 1 | 0 | |||
| Interest and dividends payable | 0 | 0 | |||||||
| Other undisclosed accounts payable and accrued liabilities | 2 | 2 | 2 | 1 | 1 | 2 | |||
| Debt | 1 | 0 | 0 | 0 | 0 | 0 | |||
| Due to related parties | 1 | 1 | 1 | 1 | 1 | 1 | |||
| Other undisclosed current liabilities | 2 | 2 | 1 | 2 | 1 | 0 | |||
| Total current liabilities: | 7 | 6 | 5 | 6 | 3 | 3 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 7 | 6 | 5 | 6 | 3 | 3 | |||
| Temporary equity, carrying amount | 0 | ||||||||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | (7) | (6) | (4) | (5) | (3) | (2) | |||
| Preferred stock | 0 | 0 | 0 | ||||||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Additional paid in capital | 159 | 159 | 157 | 152 | 145 | 139 | |||
| Accumulated deficit | (167) | (164) | (162) | (158) | (148) | (142) | |||
| Other undisclosed stockholders' equity attributable to parent | 0 | 0 | 1 | ||||||
| Total stockholders' equity: | (7) | (6) | (4) | (5) | (3) | (2) | |||
| Other undisclosed liabilities and equity | (0) | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 0 | 0 | 0 | 0 | 0 | 0 | |||
Income statement (P&L) ($ in millions)
| 9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 0 | 0 | ||||||
| Cost of revenue (Financial Services Costs) | (0) | |||||||
| Gross profit: | 0 | 0 | ||||||
| Operating expenses | (2) | (2) | (4) | (8) | (5) | (4) | ||
| Other undisclosed operating income | 0 | |||||||
| Operating loss: | (2) | (2) | (4) | (8) | (5) | (4) | ||
| Nonoperating income (expense) (Foreign Currency Transaction Gain (Loss), before Tax) | 0 | (0) | ||||||
| Interest and debt expense | (0) | (0) | (0) | (1) | (1) | (0) | ||
| Net loss: | (2) | (2) | (4) | (9) | (6) | (4) | ||
| Other undisclosed net income (loss) attributable to parent | (0) | 0 | (0) | 0 | 2 | |||
| Net loss attributable to parent: | (2) | (3) | (4) | (9) | (6) | (3) | ||
| Preferred stock dividends and other adjustments | (0) | (0) | (0) | |||||
| Other undisclosed net loss available to common stockholders, basic | (10) | |||||||
| Net loss available to common stockholders, diluted: | (2) | (3) | (4) | (9) | (6) | (13) | ||
Comprehensive Income ($ in millions)
| 9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (2) | (2) | (4) | (9) | (6) | (4) | ||
| Comprehensive loss, net of tax, attributable to parent: | (2) | (2) | (4) | (9) | (6) | (4) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.